Tyvaso (nebulized treprostinil) for Idiopathic pulmonary fibrosis
The FDA is expected to decide on Tyvaso for Idiopathic pulmonary fibrosis in Late April 2027, under a sNDA from United Therapeutics.
What is being decided
United Therapeutics has a sNDA under FDA review for Tyvaso (nebulized treprostinil) in Idiopathic pulmonary fibrosis. Would be the first inhaled antifibrotic for IPF. United Therapeutics has disclosed only that it expects the review to finish in late April 2027.
Who this decision matters to
Idiopathic pulmonary fibrosis is a chronic, progressive lung disease characterized by scarring (fibrosis) of lung tissue. The fibrosis reduces lung capacity and oxygen transfer, causing progressive dyspnea and hypoxemia. Antifibrotic drugs (pirfenidone and nintedanib) have demonstrated ability to slow disease progression.
Prevalence: About 128,000 cases in the U.S.; 3 per 100,000 person-years incidence. See our full Idiopathic Pulmonary Fibrosis page for current treatments, recruiting trials, and community resources.
About the drug
Tyvaso prostacyclin analog that dilates pulmonary blood vessels and inhibits platelet aggregation Our full Tyvaso profile covers how it works, side effects in plain language, and its trial history.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Where Idiopathic Pulmonary Fibrosis treatment stands today
Two antifibrotic medications, pirfenidone and nintedanib, have proven they can slow IPF progression and should be started as early as possible after diagnosis. Beyond these, researchers are actively testing new antifibrotic agents and anti-inflammatory therapies that target specific molecular pathways driving fibrosis, with the hope of slowing or even halting lung scarring more effectively. Combination approaches that layer multiple mechanisms together are also in trials. Getting an accurate diagnosis through clinical evaluation, high-resolution CT imaging, and sometimes lung biopsy is an important first step, since it opens the door to both approved therapies and clinical trials. The Pulmonary Fibrosis Foundation can help you find studies near you, and for patients with advanced disease, lung transplantation remains a viable option worth discussing with your care team.
Meanwhile, 115 Idiopathic Pulmonary Fibrosis trials are recruiting
Whatever the FDA decides here, research on Idiopathic Pulmonary Fibrosis does not stop. A few currently enrolling studies, US sites first:
Get notified when new idiopathic-pulmonary-fibrosis trials open or existing trials change status, add sites, or update eligibility.
Frequently asked questions
When will the FDA decide on Tyvaso?
United Therapeutics has disclosed a decision window of Late April 2027 for Tyvaso in Idiopathic pulmonary fibrosis, without an exact date.
What is Tyvaso being reviewed for?
United Therapeutics submitted a sNDA for Tyvaso in Idiopathic pulmonary fibrosis. Would be the first inhaled antifibrotic for IPF. United Therapeutics has disclosed only that it expects the review to finish in late April 2027.
What happens after the Tyvaso decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from United Therapeutics announcement. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified weekly.